> Detailanzeige

Schwarz, Ernst R.; Kersting, Philipp H.; Reffelmann, Thorsten; Meven, Dennis A.; Al-Dashti, Raja; Skobel, Erik C.; Klosterhalfen, Bernd; Hanrath, Peter

Cardioprotection by Carvedilol: Antiapoptosis is Independent of β-Adrenoceptor Blockage in the Rat Heart

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Cardioprotection by Carvedilol: Antiapoptosis is Independent of β-Adrenoceptor Blockage in the Rat Heart
  • Beteiligte: Schwarz, Ernst R.; Kersting, Philipp H.; Reffelmann, Thorsten; Meven, Dennis A.; Al-Dashti, Raja; Skobel, Erik C.; Klosterhalfen, Bernd; Hanrath, Peter
  • Erschienen: SAGE Publications, 2003
  • Erschienen in: Journal of Cardiovascular Pharmacology and Therapeutics
  • Sprache: Englisch
  • DOI: 10.1177/107424840300800306
  • ISSN: 1074-2484; 1940-4034
  • Schlagwörter: Pharmacology (medical) ; Cardiology and Cardiovascular Medicine ; Pharmacology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p> Background: Carvedilol, a β-blocking agent with α-blocking properties is now widely used for the treatment of congestive heart failure. In addition to its β-adrenergic receptor blockage, antiapoptotic effects have been demonstrated in experimental animals. </jats:p><jats:p> Objective: The cardioprotective effects of carvedilol and its hydroxylated analogue BM-91.0228 were tested with regard to their infarct-limiting and antiapoptotic properties in an experimental infarct model in the rat heart. </jats:p><jats:p> Methods: Anesthetized rats were subjected to either 30 (groups I to 3) or 60 minutes (groups. 4 to 6) of coronary artery occlusion followed by 30 minutes of reperfusion. Groups 1 and 4 served as the control; groups 2 and 5 received intravenous Carvedilol (1 mg/kg) and groups 3 and 6 received intravenous administration of BM-91.0228 (1 mg/kg), respectively, 5 minutes prior to coronary occlusion. Infarct sizes were measured by triphenyltetrazolium chloride staining. In situ visualization of apoptosis was measured by nick end labeling. </jats:p><jats:p> Results: Carvedilol reduced infarct size after 30 minutes of coronary occlusion compared to controls (8.7% ± 2.7% versus 27.3% ± 3.4%, P &lt; .001), while BM-91.0228 showed no significant infarct size reduction (23.7% ± 5.9%, NS). Neither Carvedilol (36.9% ± 3.9%) nor BM-91.0228 (42.4% ± 3.6%) reduced infarct size after 60 minutes of coronary occlusion compared to controls (47.7% ± 3.9%, NS). Carvedilol reduced apoptosis after 30 minutes (4.9% ± 1.3% versus 16.7% ± 3.2%, P &lt; .01) and after 60 minutes (11.7% ± 1.8% versus 25.5% ± 0.5%, P &lt; .001) of coronary occlusion compared to controls. BM-91.0228 reduced apoptosis after 30 minutes (7.3% ± 1.4% versus 16.7% ± 3.2%, P &lt; .01) and after 60 minutes (13.4% ± 1.8% versus 25.5% ± 0.5%, P &lt; .001) of coronary occlusion compared to controls. </jats:p><jats:p> Conclusion: Carvedilol is cardioprotective by preventing ischemia-perfusion-induced necrosis and apoptosis of cardiomyocytes. The antiapoptotic effects of Carvedilol are independent of its β-adrenoceptor blocking effects, but its effects might be caused by antioxidant properties and by modulation of the signalling pathway. </jats:p>
  • Zugangsstatus: Freier Zugang